Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

INN805

Phase 1Small molecule

FFindCure Biosciences (ZhongShan) Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Maligant Solid TumorRecruiting

Maligant Solid TumorPhase 1

Recruiting

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Maligant Solid Tumor

NCT07459283

Clinical

Trials by Indication[1]

Maligant Solid Tumor1 trial

Evaluation of the Safety, Dosimetry and Efficacy of 177Lu-INN805 Injection in Patients With Malignant Solid Tumors

Recruiting·FFindCure Biosciences (ZhongShan) Co., Ltd.·Phase 1·NCT07459283·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for INN805. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INN805 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INN805. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — FindCure Biosciences (ZhongShan) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: FFindCure Biosciences (ZhongShan) Co., Ltd.

Related News